StockNews.AI
RLMD
StockNews.AI
146 days

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

1. Relmada to host a conference call on March 27, 2025. 2. The call will discuss Q4 financial results and business progress. 3. Key investigational programs include NDV-01 for bladder cancer. 4. Sepranolone program is prepared for further studies on Tourette's Syndrome. 5. Webcast details are available on Relmada's investor website.

3m saved
Insight
Article

FAQ

Why Bullish?

The upcoming conference call could reveal positive financial or developmental news, similar to past results that often lead to price increases in biotech stocks.

How important is it?

The announcement directly pertains to RLMD’s financial outlook, which is critical for investor confidence.

Why Short Term?

Investor sentiment is likely to respond immediately to news from the conference call, aligning with how market reactions often occur around earnings announcements.

Related Companies

AMGNBMYMRK
March 26, 2025 09:00 ET  | Source: Relmada Therapeutics CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Information: Date: Thursday, March 27, 2025 at 4:30 PM ETParticipant Dial-in (US): 1-877-407-0792Participant Dial-in (International): 1-201-689-8263Conference: 13751458Webcast Access: Click Here A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar. About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations. Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational program for compulsion-related disorders including Tourette’s Syndrome into further studies. For more information, visit www.relmada.com. Investor Contact:Brian RitchieLifeSci Advisorsbritchie@lifesciadvisors.com Media Inquiries:Corporate Communicationsmedia@relmada.com

Related News